NL-OMON34301已完成2 期
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SEQUENTIAL DOSE ESCALATION STUDY OF THE SAFETY, TOLERABILITY, PHARMACODYNAMICS AND PHARMACOKINETICS OF SINGLE SUBCUTANEOUS DOSES OF HM11260C IN ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS - HM11260C SAD study in patients with type 2 diabetes mellitus
Hanmi Pharmaceutical Company Ltd0 个研究点目标入组 48 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 48
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Type 2 diabetes mellitus,
- •18 - 75 years,
- •BMI 25 - 40 kg/m2
- •Non-smoker of light smoker (inclusive)
排除标准
- •Suffering from: hepatitis B, cancer or HIV/Aids. In case of participation in another drug study within 90 days before the start of this study or being a blood donor within 90 days from the start of the study. In case of donating more than 1.5 liters blood in the 10 months preceding the start of the study.
- •Use of insuline for diabetes in the past.
研究者
相似试验
进行中（未招募）
不适用
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SEQUENTIAL DOSE ESCALATION STUDY OF THE SAFETY, TOLERABILITY, PHARMACODYNAMICS AND PHARMACOKINETICS OF SINGLE SUBCUTANEOUS DOSES OF HM11260C IN ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS - HM11260C SAD study in patients with type 2 diabetes mellitustype 2 diabetes mellitusMedDRA version: 12.1Level: LLTClassification code 10012601Term: Diabetes mellitusEUCTR2010-019665-28-NLHanmi Pharmaceutical Company Limited
已完成
不适用
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SAFETY, TOLERABILITY AND PHARMACOKINETIC STUDY OF SINGLE INTRAVENOUS DOSES OF GNX-5086 IN HEALTHY SUBJECTSAcute myocardial infarctionNL-OMON40482Congenia S.r.l.105
已完成
4 期
A clinical study to assess the benefits of Concentrace Trace Mineral Drops-(CTMD®), a food supplement in subjects with OSTEOARTHRITIS (OA) of knee jointCTRI/2010/091/001105Dr. Himanshu Bansal100
进行中（未招募）
1 期
This is a study of two investigational drugs called onartuzumab and bevacizumab that are being tested alone or in combination with each other for the treatment of a specific type of brain tumor called glioblastoma.EUCTR2011-005912-27-GBF. Hoffmann-La Roche Ltd.129
招募中
不适用
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE- AND MULTIPLE ASCENDING DOSE TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF LEO 158968 IN HEALTHY SUBJECTSNL-OMON53439eo Pharma120